Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
09/26/20168:10PMDJNMylan's EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Update
By Mark Maremont Mylan NV on Monday clarified the profit it said it made from its lifesaving EpiPen drug, days after House members badgered the company's chief executive to justify the device's steep price increases. Testifying before a congressional committee last week, CEO Heather Bresch said Mylan's profit... More...>>
09/26/201611:50AMDJNMylan Clarifies EpiPen Profit Figures it Provided to Congress Last Week
When Mylan NV's chief executive testified before a congressional committee last week about steep price increases on its lifesaving EpiPen drug, House members badgered her to provide more evidence for the company's claim that its profits were just $100 for a two-pack of the injectors, despite a $608 list price... More...>>
09/21/201610:50AMDJNMylan CEO to Shift Blame on EpiPen Pricing at Hearing
Mylan NV CEO Heather Bresch plans to defend the rising price of EpiPens when testifying before Congress Wednesday, sticking to the company's effort to shift blame to health insurers and drug-benefit managers. Since scrutiny of EpiPen's price intensified, the company has sought to point fingers at the other health-system... More...>>
09/14/201611:20PMDJNEpiPen Maker Executive to Testify at House Hearing
WASHINGTON—Lawmakers have summoned the top executive from EpiPen maker Mylan NV to Washington for a hearing next week to explain substantial price increases for the emergency allergy treatment that have generated widespread consumer outrage. The company confirmed Wednesday that Chief Executive Heather Bresch will... More...>>
09/11/201611:20PMDJNStarboard Value Takes 4.6% Stake in Perrigo
Starboard Value LP has built a 4.6% stake in Perrigo Co., worth nearly $600 million, and is urging the drug company to refocus on its core business. The activist shareholder sent Perrigo a letter Sunday criticizing the company for failing to live up to performance targets it set while successfully fending off a $26 billion... More...>>
09/01/20163:12PMPRNUSMylan Invalidates Third Teva Copaxone® 40 mg/mL Patent Via U.S. Patent and Trademark Office's Inter Partes Review Proceeding
Mylan Invalidates Third Teva Copaxone® 40 mg/mL Patent Via U.S. Patent and Trademark Office's Inter Partes Review Proceeding PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Sept. 1, 2016 HERTFORDSHIRE, England and PITTSBURGH, Sept. 1, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the U.S... More...>>
09/01/20168:20AMDJNEpiPen Maker Mylan Tied Pay to Aggressive Profit Targets
The drugmaker at the center of a firestorm over hefty price increases on the lifesaving EpiPen put a special incentive plan in place more than two years ago that rewards executives if they hit aggressive profit targets. In early 2014, the board of Mylan NV approved a one-time award for more than 100 employees that hinged... More...>>
08/29/20168:10AMDJNMylan, Feeling Heat on EpiPen Price, Will Offer Cheaper Generic
Mylan NV on Monday said it would launch a generic alternative to EpiPen at a 50% discount after being criticized for dramatically raising the price of the lifesaving drug. The company said it would list the authorized generic—which will be identical to the branded product—for $300 per two-pack carton. Mylan... More...>>
08/29/20166:00AMPRNUSMylan to Launch First Generic to EpiPen® Auto-Injector at a List Price of $300 per Two-Pack Carton, a More than 50% Discount...
Mylan to Launch First Generic to EpiPen® Auto-Injector at a List Price of $300 per Two-Pack Carton, a More than 50% Discount to the Brand Product PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 29, 2016 HERTFORDSHIRE, England and PITTSBURGH, Aug. 29, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced... More...>>
08/25/20169:45AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to trade actively in Thursday's session are Medtronic PLC (MDT), Signet Jewelers Ltd. (SIG) and Sears Holdings Corp. (SHLD). Medtronic PLC said sales fell in the latest period across most of its segments, though the medical device maker's profit grew thanks to lower expenses... More...>>
08/25/20168:30AMDJNMylan Boosts Price Assistance for EpiPen Amid Backlash
Mylan NV responded Thursday to backlash over price increases for its EpiPen emergency allergy treatment by promising to reduce the costs that some patients pay, though the drugmaker stopped short of saying it would roll back prices or limit future increases. EpiPen is a lifesaving treatment for millions whose allergies... More...>>
08/25/20167:00AMPRNUSMylan Taking Immediate Action to Further Enhance Access to EpiPen® (Epinephrine Injection, USP) Auto-Injector
Mylan Taking Immediate Action to Further Enhance Access to EpiPen® (Epinephrine Injection, USP) Auto-Injector Mylan doubling the eligibility for patient assistance, effectively eliminating out-of-pocket expense for uninsured and under-insured patients Company to cover up to $300 of out-of-pocket cost at pharmacy; reducing... More...>>
08/25/20166:30AMPRNUSMylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines...
Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency PR Newswire BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2016 BENGALURU, India and HERTFORDSHIRE, England and PITTSBURGH, Aug. 25, 2016 /PRNewswire/ -- Mylan N.V... More...>>
08/24/20166:20PMDJNMylan Faces Scrutiny Over EpiPen Price Increases
Mylan NV became the latest pharmaceutical company to face popular outrage about higher drug costs, as attacks mounted Wednesday on the company's substantial price increases for the EpiPen emergency allergy treatment. EpiPen is a lifesaving treatment for millions whose allergies can send them into severe shock, including... More...>>
08/24/20164:47PMPRNUSMylan Invalidates Two of Teva's Copaxone® 40 mg/mL Patents Via U.S. Patent and Trademark Office's Inter Partes Review Procee...
Mylan Invalidates Two of Teva's Copaxone® 40 mg/mL Patents Via U.S. Patent and Trademark Office's Inter Partes Review Proceeding PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 24, 2016 HERTFORDSHIRE, England and PITTSBURGH, Aug. 24, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the... More...>>
08/11/20169:00AMPRNCABreathing Easier: Pharma Successfully Leveraging Smoother EU Regulatory Specs
Breathing Easier: Pharma Successfully Leveraging Smoother EU Regulatory Specs Canada NewsWire BOSTON, MA, Aug. 11, 2016 Pharma developer Pulmatrix, Inc. [NASDAQ:PULM], partnership with industry giant Mylan [NASDAQ:MYL] BOSTON, MA, Aug. 11, 2016 /CNW/ - [NASDAQ:PULM]: It's been less than two months since the Brexit... More...>>
08/11/20169:00AMPRNUSBreathing Easier: Pharma Successfully Leveraging Smoother EU Regulatory Specs
Breathing Easier: Pharma Successfully Leveraging Smoother EU Regulatory Specs PR Newswire BOSTON, MA, Aug. 11, 2016 Pharma developer Pulmatrix, Inc. [NASDAQ:PULM], partnership with industry giant Mylan [NASDAQ:MYL] BOSTON, MA, Aug. 11, 2016 /PRNewswire/ - [NASDAQ:PULM]: It's been less than two months since the Brexit... More...>>
08/10/20169:00AMDJNPerrigo Misses Expectations and Cuts Guidance
Drugmaker Perrigo Co. on Wednesday said it missed earnings expectations for the latest quarter and cut its guidance for the year as it continues to battle pricing pressure and competition in the market. Perrigo stock, which has lost more than half its value over the past 12 months, dropped 12% premarket to $83.39. "Our... More...>>
08/09/20166:10PMDJNMylan Backs Year View After Sales Rise 8%
Mylan NV logged 8% second-quarter sales growth, driven by a jump in specialty drug sales and higher sales of generic treatments. The pharmaceutical giant last month won regulatory clearance for its $7.2 billion acquisition of Swedish rival Meda. The deal comes about a year after Mylan fended off Israeli generic drugmaker... More...>>
08/09/20164:02PMPRNUSMylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8%
Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8% PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Aug. 9, 2016 HERTFORDSHIRE, England and PITTSBURGH, Aug. 9, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and six months ended... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V:us D:20160927 22:21:29